CD8A and cancer: Some studies have found that S100A5 weakens the killing of BLCA cells by effector T cells by inhibiting CD8+ T cell proliferation and cytotoxicity, thereby exerting anti-cancer immunity and further reducing the effectiveness of anti-PD-L1/PD-1 immunotherapy (Li et al., 2023).